# Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

> **NCT01081223** · PHASE1,PHASE2 · COMPLETED · sponsor: **TVAX Biomedical** · enrollment: 12 (actual)

## Conditions studied

- Glioma
- High Grade Astrocytoma
- Glioblastoma Multiforme

## Interventions

- **BIOLOGICAL:** Cancer vaccine plus immune adjuvant

## Key facts

- **NCT ID:** NCT01081223
- **Lead sponsor:** TVAX Biomedical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04
- **Primary completion:** 2011-03
- **Final completion:** 2011-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01081223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01081223, "Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01081223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*